Rheumatoid Arthritis & Interstitial Lung Disease Medication

Trial Objective

Rheumatoid Arthritis & Interstitial Lung Disease MedicationThe purpose of this study is to find out if people with rheumatoid arthritis and interstitial lung disease (ILD) can benefit from taking Pirfenidone.

Our researchers also want to determine if the medication can be taken safely without many side effects. Pirfenidone is approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). This study will compare the results of taking Pirfenidone to those of a placebo, a medication that looks like Pirfenidone but does not contain the drug. Participants may receive Pirfenidone or a placebo.


New enrollment for this trial is temporarily paused

Who Can Participate

Adults who have been diagnosed with rheumatoid arthritis and interstitial lung disease (RA-ILD) for at least six months.

Age: 18-85    Gender: Any Gender

Estimated Time Commitment

10 visits & 1 phone call (22 hours over 56 weeks)

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Kris Eliopoulos

Kris Eliopoulos

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Genentech, Inc.

Principal Investigators

Request More Information

After limiting clinical research activity due to safety concerns about COVID-19, we are now restarting clinical research in stages. If you are interested in any of the clinical trials posted on our website, please request trial information. We will respond and share the timing for enrollment resuming. Learn More